{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"12.2","value":"5.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Overall survival is the time interval from the start of treatment to the date of death.","dispersionType":"95% Confidence Interval","groups":[{"description":"20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)","id":"OG000","title":"IMC-A12 Monotherapy in Patients"}],"paramType":"MEDIAN","populationDescription":"One participant withdrew from the study and was excluded from the analysis.","reportingStatus":"POSTED","timeFrame":"To study completion, an average of 3 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}